Healthcare & Life Sciences

Design Patent USD1124351S1 - Medical Trolley Handle, GE Precision Healthcare, Apr 28 2026

The USPTO granted Design Patent USD1124351S1 covering the ornamental design of a medical trolley handle to GE Precision Healthcare LLC. The patent application was filed on January 19, 2024 under Application No. 29924707 and claims priority to a single claim. The invention relates to medical devices including dialysis equipment and patient monitoring systems as indicated by its CPC classifications.

Continuous Glucose Monitoring Transmitter Design Patent USD1124355S1

USPTO granted Design Patent USD1124355S1 on April 28, 2026, covering the ornamental design of a continuous glucose monitoring transmitter. The patent lists Bozhen Sun and Hao Hua as the sole inventors. The patent application was filed on December 25, 2024, under Application No. 35523724, and includes one design claim. CPC classifications span medical device monitoring systems, glucose measurement, and physiological signal processing.

Coloplast Anal Irrigation Container Design, USD1124322S1

The USPTO granted Design Patent USD1124322S1 to Coloplast A/S for an anal irrigation container. The patent application (No. 29907927) was filed on January 10, 2024, and issued April 28, 2026. The design is classified under CPC categories A61M 3/0262, A61M 3/0266, A61M 3/027, and A61M 3/06, covering irrigation systems for the digestive tract. Inventors credited include Kristian Bjarklev, Niels Frederik Keiser-Nielsen, Richard Morgan Hickmott, and Ignacio Javier D'Avola. The patent includes 1 claim.

Anal Irrigation Container - Coloplast A/S, Design USD1124321S1

The USPTO granted Design Patent USD1124321S1 to Coloplast A/S for an anal irrigation container. The patent, filed on January 10, 2024 under application number 29907925, names four inventors: Kristian Bjarklev, Niels Frederik Keiser-Nielsen, Richard Morgan Hickmott, and Ignacio Javier D'Avola. The design is classified under CPC codes A61M 3/0262, A61M 3/0266, A61M 3/027, and A61M 3/06, covering medical irrigation devices.

USD1124315S1 Design Patent - Medicine Injector - PHC Holdings

The USPTO granted Design Patent USD1124315S1 to PHC Holdings Corporation for a medicine injector design. The patent, classified under CPC A61M (medical devices), was filed on February 23, 2024 under application number 29929705 and includes one design claim. Inventors Masakazu Mori, Noriyuki Shinohara, and Yuta Moriwake are credited on the filing.

Amgen Design Patent: Handheld Drug Delivery Device, USD1124318S1

The USPTO granted Amgen Inc. Design Patent USD1124318S1 for a handheld drug delivery device on April 28, 2026. The patent application (No. 29982645) was filed on January 7, 2025, and lists eight inventors: Austin Davis, Lars Eilertsen, David Lavmand Muller, Rasmus Ohlenschlaeger, Gregory Thomas Nowak, Kasper Poder, and Dylan Bourelle. The patent contains one claim and is classified under CPC codes related to drug delivery mechanisms including A61M 5/3156, A61M 5/31591, and related subcategories.

Sensile Medical AG Medicine Injector Design Patent USD1124316S1

The USPTO granted Design Patent USD1124316S1 to Sensile Medical AG on April 28, 2026, for a medicine injector. The patent application was filed on May 23, 2024, under Application No. 29943726. Three inventors—Joachim Axel Fett, Simon Bürdel, and Milan Kolenda—are credited on the patent, which carries one claim under CPC classifications A61M 5/3156, A61M 5/31591, A61M 5/3155, A61M 5/31501, A61M 5/3157, and A61M 5/14566.

Coloplast Anal Irrigation Container Design USD1124320S1

The USPTO granted Design Patent USD1124320S1 to Coloplast A/S for an anal irrigation container design on April 28, 2026. The patent was filed on January 10, 2024 with application number 29907923. Four inventors are listed: Kristian Bjarklev, Niels Frederik Keiser-Nielsen, Richard Morgan Hickmott, and Ignacio Javier D'Avola. The patent contains 1 claim.

Sensile Medical AG Medicine Injector Design Patent

USPTO granted design patent USD1124317S1 to Sensile Medical AG for a medicine injector under A61M classification, filed August 28, 2024 and issued April 28, 2026. The patent contains one design claim. This represents a routine USPTO design patent grant for Sensile Medical AG.

The Monarch Company LLC Blood Collection Device Design Patent USD1124314S1

Design Patent USD1124314S1 for a blood collection device was granted to The Monarch Company LLC on April 28, 2026. The patent has 1 claim and was filed on February 20, 2024 under Application No. 29929221. Inventor is Jonathan Trawick, with CPC classifications A61M 25/0606, A61M 25/0693, and A61M 25/0643. As a design patent, this protects the ornamental appearance of the device rather than its functional aspects.

WV Board of Pharmacy Transitions to Online Applications and Digital Permits

The West Virginia Board of Pharmacy announced on April 27, 2026, that all new applications and renewal applications for pharmacy licenses and permits must be submitted through the online portal. Physical permits and licenses will no longer be printed and mailed. Instead, applicants and licensees will receive an emailed link to access and print their permit or license, sent to the email address on file with the Board. Licensees who require a printed and mailed copy must contact the Board office or email boardofpharmacy@wv.gov to make a request.

WV Board of Pharmacy Implements UMPJE for Pharmacist Licensure August 1, 2026

The WV Board of Pharmacy has voted to replace the West Virginia-specific Multistate Pharmacy Jurisprudence Exam (WV-MPJE) with the Uniform Multistate Pharmacy Jurisprudence Exam (UMPJE) effective August 1, 2026. UMPJE eligibility applications will open May 4, 2026, with candidates able to choose either exam through July 31, 2026. After passing the UMPJE, pharmacists receive a 90-day provisional license and must complete a WV-Plus Module (asynchronous webinar plus open-note quiz) to obtain a full license through the next renewal cycle.

AGENSYS Cancer Peptide Patent US12612429B2 Granted April 2026

USPTO granted patent US12612429B2 to AGENSYS, INC. on April 28, 2026 for derivatives of dolaproine-dolaisoleuine peptide analogs and pharmaceutical compositions for treating cancer. The patent names Brian Alan Mendelsohn, Julien Dugal-Tessier, and Stuart Daniel Barnscher as inventors, with 16 claims allowed. The application was filed on March 18, 2022 under application number 17698353.

Regeneron PCSK9 Stabilized Antibody Formulation Patent Granted

The USPTO granted Regeneron Pharmaceuticals patent US12612466B2 covering stabilized pharmaceutical formulations of human anti-PCSK9 antibodies. The formulations include at least one amino acid, sugar, or non-ionic surfactant to achieve substantial antibody stability after storage for several months. The patent contains 7 claims and was filed on April 28, 2023.

Fusion Polypeptide Comprising Immunoglobulin Hinge Region for Extended In Vivo Period

The USPTO issued US Patent 12,612,469 B2 to LG CHEM, LTD. on April 28, 2026, granting exclusive rights to a fusion polypeptide technology comprising a target polypeptide fused to an immunoglobulin hinge region, which may be used to extend the in vivo half-life of therapeutic proteins. The patent application was originally filed on September 4, 2019, and contains 10 claims covering the fusion polypeptide composition, pharmaceutical compositions containing it, and methods of increasing protein circulation time. This grant provides LG Chem with intellectual property protection that precludes competitors from practicing the specified fusion polypeptide technology in the United States.

Skyhawk Therapeutics Patent Granted for RNA Splicing Modulators

USPTO granted patent US12612397B2 to Skyhawk Therapeutics, Inc. on April 28, 2026, covering small molecule splicing modulator compounds and pharmaceutical compositions for modulating mRNA splicing to treat disease. The patent names inventors Michael Luzzio, Brian Lucas, and Daniel Brian Horne, with 14 allowed claims under CPC classifications C07D 451/06 and C07D 451/14. Filing date was July 29, 2021, under application number 17388097.

US12612392B2: ISR Pathway, eIF2B Heterocyclic Compounds Patent Granted

The USPTO granted patent US12612392B2 to Shenzhen Zhongge Biological Technology Co., Ltd. on April 28, 2026, covering heterocyclic compounds designed to reduce cellular integrated stress response (ISR) and activate eIF2B activity. The patented compounds aim to enable normal cellular protein synthesis for treating ISR pathway-mediated diseases and eIF2B-related conditions. The patent includes 4 claims and covers the compound structure, pharmaceutical compositions, synthesis methods, and therapeutic applications.

US12612389B2 - Anticancer Benzofuran Derivative Patent Grant

The USPTO granted US Patent 12612389B2 to the Korea Research Institute of Bioscience and Biotechnology for a benzofuran-based N-acylhydrazone derivative demonstrating anticancer activity. Filed July 14, 2020 under application number 17627547, the patent contains 19 claims under CPC classification C07D 405/12. The invention is characterized as having low toxicity and excellent solubility alongside its anticancer efficacy, making it suitable for pharmaceutical compositions treating cell proliferative disorders and various cancers.

Constellation Pharmaceuticals Granted Patent US12612390B2

The USPTO granted Patent US12612390B2 to Constellation Pharmaceuticals, Inc. on April 28, 2026. The patent covers novel compounds of Formula (I) and their pharmaceutical salts, which function as modulators of methyl modifying enzymes for treating diseases, disorders, and conditions associated with these enzymes. The application (No. 18140730) was filed on April 28, 2023, and contains 6 claims.

Sironax Granted Patent for RIP1 Kinase Inhibitors

USPTO granted patent US12612388B2 to Sironax Ltd. on April 28, 2026, covering receptor-interacting protein 1 (RIP1) kinase inhibitors including piperazine heterocyclic amide urea compounds, along with corresponding sulfonamides and stereoisomers. The patent also protects related pharmaceutical compositions and methods of treatment for conditions addressable by RIP1 inhibition. The filing date was May 20, 2021, with 25 claims allowed across three CPC classifications.

Shanghai Wennai Therapeutics US12612383B2 Pyrrolidine Derivative Nav1.8 Inhibitor

The USPTO granted Patent US12612383B2 to SHANGHAI WENNAI THERAPEUTICS CO., LTD. on April 28, 2026, covering polysubstituted pyrrolidine derivative compounds, their stereoisomers, tautomers, deutero-derivatives, and pharmaceutically acceptable salts. The patented compounds function as sodium channel subtype Nav1.8 inhibitors and are intended for pharmaceutical use in the treatment and prevention of pain-related disorders. The patent contains 8 claims and lists Shanghai Yu as the sole inventor.

US12612385B2 Heterocyclic Compounds Targeting Pathogenic Blood Vessels

The USPTO granted Patent US12612385B2 to The Regents of the University of California on April 28, 2026, covering heterocyclic compounds and compositions for modulating PLXDC1 (TEM7) and/or PLXDC2, killing pathogenic blood vessels, and treating diseases mediated by PEDF receptors or angiogenesis. The patent contains 11 claims and names six inventors including Hui Sun, Pu Sun, Guo Cheng, Adrian Chichuen Au, and Ming Zhong. The application was filed on November 27, 2023 under application number 18519938.

Design Patent USD1124363S1, Corrective Back Brace

The USPTO granted Design Patent USD1124363S1 to inventor Siqi Yan on April 28, 2026, covering a corrective back brace design. The patent application (No. 29981294) was filed on December 30, 2024, and carries CPC classifications A61F 5/026 and A61F 5/028. The patent includes one design claim protecting the ornamental appearance of the corrective back brace.

Design Patent USD1124364S1, Think Green Limited, 28th Apr

The USPTO granted Design Patent USD1124364S1 to Think Green Limited on April 28, 2026, for a nipple corrector device. The patent application (No. 29990675) was filed on February 24, 2025, with Shuting Zhang listed as the sole inventor. CPC classifications include A61F 2/52, A61F 13/141, and related prosthodontics and protective device categories, indicating a wearable medical device. Think Green Limited now holds enforceable design patent rights in the United States under this grant.

Design Patent USD1124365S1, Knee Therapy Pad

The USPTO granted Design Patent USD1124365S1 for a knee therapy pad to Shenzhen Rainbow Light Medical Equipment Co., Ltd. on April 28, 2026. The design patent, which claims one design, was filed on April 30, 2025 under Application No. 30001730. Inventors are Cao Jiaming and Alain Dijkstra. This grant establishes the assignee's exclusive ornamental design rights for the knee therapy pad.

Tourniquet for Magnetic Resonance Angiography - Design USD1124361S1

The USPTO granted Design Patent USD1124361S1 to Martin R. Prince on April 28, 2026, covering the ornamental design of a tourniquet intended for use in magnetic resonance angiography procedures. The patent application (No. 29956906) was filed on August 9, 2024, and includes one claim covering the design configuration as shown in the drawings.

Skin Patch Design Patent USD1124359S1, Church & Dwight

The USPTO granted Design Patent USD1124359S1 for a skin patch to Church & Dwight Co., Inc. on April 28, 2026. The patent application (No. 29971249) was filed on November 1, 2024, with CPC classifications covering absorbent pads and adhesive skin attachments under A61F13/00. The design patent contains one claim.

Animal-Head-Shaped Medical Patch Design USD1124360S1

USPTO granted design patent USD1124360S1 to ExpressionMed LLC for an animal-head-shaped medical patch on April 28, 2026. The inventors are Meghan Sharkus, Kelsey Nolan, and Bjorn Berg. The patch carries CPC classifications A61F 13/0206, A61F 13/025, A61F 13/0259, A61F 2013/00544, C09J 2301/204, C09J 7/20, Y10S 428/906, Y10T 428/14, and Y10T 428/1476, and was filed under Application No. 30019667 on August 25, 2025.

Design Patent USD1124358S1, Menstrual Pain Device

The USPTO granted Design Patent USD1124358S1 to Juno Technologies Inc. on April 28, 2026, for a menstrual pain management device. The patent was filed on October 19, 2023, under Application No. 29914558, with one claim allowed. CPC classifications span A61F (medical/medical dressings), C09J (adhesives), and A61N (electrotherapy/devices including electrical nerve stimulation for pain management).

EZUROTECH Catheter Design Patent USD1124312S1 Granted

The United States Patent and Trademark Office granted design patent USD1124312S1 to EZUROTECH Co., Ltd. on April 28, 2026, covering the ornamental design of a catheter. The patent application was filed on August 8, 2024, under Application No. 29956604, with Hye Jin Kim and Mi Kyoung Kang listed as inventors. CPC classifications indicate the design relates to medical measurement devices for catheters (A61B 5/6852 through A61B 5/6858). The patent contains one design claim.

Design Patent USD1124332S1, Liposuction Device, April 28 2026

USPTO granted Design Patent USD1124332S1 for a liposuction device to inventor Xuying Zhao on April 28, 2026. The patent application (No. 29999317) was filed on April 16, 2025, and contains 1 claim. Design patents protect ornamental design rather than functional aspects.

Design Patent USD1124328S1 - Fiducial Delivery Device, AskBio Inc

USPTO granted Design Patent USD1124328S1 for a fiducial delivery device to ASKIPO INC. The patent, dated April 28, 2026, covers the ornamental design of the device and lists six inventors including Adrian P. Kells and Krystof S. Bankiewicz. The application was filed August 6, 2024, under Application No. 29956223, with CPC classifications in surgical guidance and navigation systems (A61B 90/11, A61B 34/20, A61B 17/17).

Endoscopic Puncture Needle Design USD1124338S1 by Olympus

The United States Patent and Trademark Office granted Design Patent USD1124338S1 to OLYMPUS MEDICAL SYSTEMS CORP. for an endoscopic puncture needle on April 28, 2026. The patent, with a single claim, covers the ornamental design of the endoscopic puncture needle device; the underlying application was filed on May 19, 2023. The design patent provides Olympus with 15 years of exclusive rights to the ornamental design as of the grant date.

Seoul National University Hospital Design Patent USD1124343S1

USPTO granted Design Patent USD1124343S1 to SEOUL NATIONAL UNIVERSITY HOSPITAL on April 28, 2026. The patent covers an ophthalmic medical device designed by inventor Se Joon Woo. The filing was submitted on January 30, 2024 under Application No. 35520532, with one design claim.

Design Patent USD1124080S1 - Industrial Robot

Kuka Robotics Manufacturing China Co., Ltd. was granted Design Patent USD1124080S1 for an industrial robot design, published on April 28, 2026. The patent application (No. 35524469) was filed on March 25, 2024, with inventors Sivakumar Thangavelu and Lihua Kang, and contains one design claim. The invention is classified under multiple CPC codes including A61B 34/30, B25J 9/047, and B25J 17/00.

Kuka Robotics Industrial Robot Design Patent USD1124081S1

Kuka Robotics Manufacturing China Co., Ltd. received design patent USD1124081S1 for an industrial robot, granted April 28, 2026. The patent covers an ornamental design for an industrial robot with CPC classifications spanning medical/surgical robots (A61B 34/30, A61B 34/37) and general robotics/manipulators (B25J series, B66F series). The application (No. 35524504) was filed March 25, 2024, and the patent contains 1 claim. Inventors include Sivakumar Thangavelu, Qiliang Zhu, Zhichuang Zhang, Xugao Deng, and Shulin Gong.

DePuy Distal Cutting Block Design Patent, Apr 28

DePuy Ireland Unlimited Company received US Design Patent USD1124333S1 for a Distal cutting block on April 28, 2026. The patent, filed January 22, 2024 under application number 29924876, lists 6 inventors and contains 1 claim. Design patents protect the ornamental appearance of a medical device rather than its functional aspects.

Tafoxiparin for Spontaneous Labor Onset

The USPTO has granted Patent US12611423B2 to DILAFOR AB for tafoxiparin as a medical compound for inducing spontaneous labor onset in term pregnant women. The patent covers administration of tafoxiparin at a daily dose of 30-320 mg. The patent contains 22 claims and lists Lena Degling-Wikingsson and Gunvor Ekman-Ordeberg as inventors.

GM1 Liposomal Composition Patent for Parkinson's Disease Treatment

INNOMEDICA HOLDING AG has been granted US Patent US12611419B2 for a method of treating Parkinson's disease using a liposomal composition comprising sphingomyelin in a lipid bilayer and a therapeutically effective amount of GM1. The patent, granted April 28, 2026, contains 17 claims and covers the therapeutic composition and its use in the specified treatment method.

AXSOME THERAPEUTICS Meloxicam Patent US12611413B2

AXSOME THERAPEUTICS INC. has been granted US Patent 12611413B2 covering pharmaceutical compositions comprising meloxicam in combination with cyclodextrin and/or carbonate or bicarbonate, filed July 8 2025 and granted April 28 2026. The patent relates to compositions that improve bioavailability and pharmacokinetics of meloxicam for treating pain conditions including migraine and arthritis, with 26 total claims. This represents a new enforceable patent grant conferring exclusive rights to the patented compositions and methods.

Celecoxib Lipid Prodrugs for Metabolic Disease

US Patent 12611415B2 (B2 kind, 10 claims) issued to MONASH UNIVERSITY on 2026-04-28. The patent covers methods of treating metabolic diseases including obesity, insulin resistance, and type 2 diabetes with celecoxib lipid prodrugs that promote transport of the pharmaceutical agent to the lymphatic system and enhance release of the parent agent.

CCR9 Antagonist Compounds for Treating Inflammation

The USPTO granted Patent US12611404B2 to ChemoCentrix, Inc. on April 28, 2026, covering aza-aryl 1H-pyrazol-1-yl benzene sulfonamide compounds that function as CCR9 receptor antagonists. The patent lists 10 named inventors including Xi Chen, Junfa Fan, and Pingchen Fan. Animal testing cited in the abstract demonstrates these aryl sulfonamide derivatives are useful for treating inflammation, a CCR9-mediated disease, and may also be used as controls in assays for identifying CCR9 antagonists. The patent application was filed on October 29, 2021.